SPRY (ARS Pharmaceuticals) Total Liabilities: $226.26 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRY ARS Pharmaceuticals Inc SPRY
28 GF Score
Price $6.06
! 5 Warning Signs
View Full Analysis

What is ARS Pharmaceuticals Total Liabilities?

ARS Pharmaceuticals SPRY +1.51% 28 Total Liabilities is $226.26 Mil as of Mar. 2026. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

ARS Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $226.26 Mil.

ARS Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 ($225.15 Mil) to Dec. 2025 ($213.39 Mil) but then increased from Dec. 2025 ($213.39 Mil) to Mar. 2026 ($226.26 Mil).

ARS Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 ($2.43 Mil) to Dec. 2024 ($94.36 Mil) and increased from Dec. 2024 ($94.36 Mil) to Dec. 2025 ($213.39 Mil).

ARS Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for ARS Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARS Pharmaceuticals Total Liabilities Chart

ARS Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 92.72 8.55 2.43 94.36 213.39

ARS Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.34 121.15 225.15 213.39 226.26
SPRY
28GF Score
ARS Pharmaceuticals Inc SPRY
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ARS Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ARS Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.145+(96.374+76.745
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1.13+0+0)
=213.39

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=327.652-114.258
=213.39

ARS Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=49.612+(96.522+79.151
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.978+0+0)
=226.26

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=287.571-61.308
=226.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $226.26 Mil mean?
ARS Pharmaceuticals (SPRY) has a Total Liabilities of $226.26 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ARS Pharmaceuticals and its competitors.
Is ARS Pharmaceuticals' Total Liabilities too high?
ARS Pharmaceuticals' current Total Liabilities is $226.26 Mil. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' Total Liabilities compare to ALLO and CBIO?
ARS Pharmaceuticals' Total Liabilities of $226.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ARS Pharmaceuticals and its competitors. ARS Pharmaceuticals's current Total Liabilities is $226.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current Total Liabilities of $226.26 Mil. The current Total Liabilities is $226.26 Mil. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current Total Liabilities is $226.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ARS Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score

Get the complete analysis for SPRY

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.06
Price